“Respiratory Compromise: Risk Prediction on the General Care Floor”
Saxe Communications & Medtronic present*… as part of the New Monitoring Strategies to Improve Outcomes series, “Respiratory Compromise: Risk Prediction on the General Care Floor”
Opioid-induced respiratory depression (OIRD), a form of respiratory compromise, is one of the leading avoidable patient safety issue. Respiratory compromise, increases morbidity and mortality as well hospital inpatient costs. This presentation will discuss the results of a recent, multi-center study PRODIGY designed to identify people at high risk for OIRD. Results showed that more than 40% of patients on the general care floor experienced OIRD. The investigators will share an easy-to-use risk prediction tool they developed to identify patients at high risk that can lead to earlier interventions.
+Continuous oximetry/capnometry monitoring reveals frequent desaturation and bradypnea during patient-controlled analgesia. Anesth Analg.2007;105(2):412—418.
Learning Objectives | Upon completion of this activity, the participant will be able to:
- Discuss current recommendations regarding vital sign surveillance by patient safety and regulatory organizations
Describe implementation strategy for continuous respiratory monitoring
Continuing Education for Physicians, Nurse Anesthetists, Nurses and Respiratory Therapists
This program has been approved for 1.0 contact hour. SynAptiv is accredited by the Accreditation Council for Coninuing Medical Education (ACCME) for 1 AMA PRA Category 1 credit.
This program has been prior approved by the American Association of Nurse Anesthetists for 1.0 Class A CE credits.
Continuing Respiratory Care Education (CRCE) credit by the American Association of Respiratory Care, 9425 N.MacArthur Blvd. Suite 100, Irving, TX 75063.
This education activity is approved for 1.0 contact hour. Provider approved by California Board of Nursing, Provider #14477 and the Florida Board of Nursing Provider #50-17032.
Support for this educational activity from Medtronic
Questions should be addressed to: Emily Eberly at 513-579-0800; email@example.com
* NOTE: This is a contracted supplier-sponsored webinar. HealthTrust has not approved and/or endorsed the content. This program may contain the mention of products, services, drugs or brands presented in a case study or comparative format. Such examples are intended for educational and informational purposes and should not be perceived as a HealthTrust endorsement of any particular supplier, product, service, drug, brand or approach.